seif

Seif is a biotechnology company focused on the development of senolytic therapies and longevity-enhancing treatments. Founded by prominent aging researcher Mikhail Blagosklonny, the company leverages insights into cellular senescence and the mechanistic target of rapamycin (mTOR) pathway to address age-related decline. Seif's primary objective is to identify and develop pharmacological agents that selectively eliminate senescent cells or modulate aging pathways to extend healthy lifespan. The company operates at the intersection of geroscience and drug discovery, aiming to translate fundamental longevity research into clinical applications for chronic age-related conditions.